• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-X filed by Taiwan Liposome Company, Ltd.

    9/15/21 11:56:53 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care
    Get the next $TLC alert in real time by email
    F-X 1 d167960dfx.htm FORM F-X Form F-X

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM F-X

     

     

    APPOINTMENT OF AGENT FOR SERVICE OF

    PROCESS AND UNDERTAKING

     

     

     

    A.

    Name of issuer or person filing (“Filer”): Woods Investment Co., Ltd.

     

    B.      (1)

    This is an (check one)

    ☒ original filing for the Filer

    ☐ amended filing for the Filer

      (2)

    Check following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rule 101(b)(9) ☐

     

    C.

    Identify the filing in conjunction with which this Form is being filed:

    Name of registrant    Taiwan Liposome Company, Ltd.
    Form type    Form CB
    File Number (if known)    Not available
    Filed by    Taiwan Liposome Company, Ltd.
    Date Filed    September 15, 2021 (filed Concurrently)

     

    D.

    The Filer is incorporated or organized under the laws of Republic of China and has its principal place of business at 11F-1, No. 3 Yuanqu Street, Nangang District, Taipei City, Taiwan 11503, Republic of China (Telephone number: +886 2 2655 7377).

     

    E.

    The Filer designates and appoints TLC Biopharmaceuticals, Inc. (“Agent”) located at 611 Gateway Blvd., Suite 830, South San Francisco, CA94080 (Telephone number: (650) 872-8816) as the agent of the Filer upon whom may be served any process, pleadings, subpoenas, or other papers in

      (a)

    any investigation or administrative proceeding conducted by the Commission; and

      (b)

    any civil suit or action brought against the Filer or to which the Filer has been joined as defendant or respondent, in any appropriate court in any place subject to the jurisdiction of any state or of the United States or of any of its territories or possessions or of the District of Columbia, where the investigation, proceeding or cause of action arises out of or relates to or concerns (i) any offering made or purported to be made in connection with the securities registered or qualified by the Filer on Form CB on August 5, 2021 or any purchases or sales of any security in connection therewith; (ii) the securities in relation to which the obligation to file an annual report on Form 40-F arises, or any purchases or sales of such securities; (iii) any tender offer for the securities of a Canadian issuer with respect to which filings are made by the Filer with the Commission on Schedule 13E-4F, 14D-1F or 14D-9F; or (iv) the securities in relation to which the Filer acts as trustee pursuant to an exemption under Rule 10a-5 under the Trust Indenture Act of 1939. The Filer stipulates and agrees that any such civil suit or action or administrative proceeding may be commenced by the service of process upon, and that service of an administrative subpoena shall be effected by service upon such agent for service of process, and that service as aforesaid shall be taken and held in all courts and administrative tribunals to be valid and binding as if personal service thereof had been made.

     

    F.

    Each person filing this Form in connection with:

      (a)

    the use of Form F-10, 40-F or Schedule 13E-4F, 14D-1F or 14D-9F stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date the issuer of the securities to which such Forms and Schedules relate has ceased reporting under the Exchange Act;

      (b)

    the use of Form F-8, Form F-80 or Form CB stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed following the effective date of the latest amendment to such Form F-8, Form F-80 or Form CB;

      (c)

    its status as trustee with respect to securities registered on Form F-7, F-8, F-10, F-80 stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time during which any of the securities subject to the indenture remain outstanding; and

      (d)

    the use of Form 1-A or other Commission form for an offering pursuant to Regulation A stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date of the last sale of securities in reliance upon the Regulation A exemption.

    Each filer further undertakes to advise the Commission promptly of any change to the Agent’s name or address during the applicable period by amendment of this Form, referencing the file number of the relevant form in conjunction with which the amendment is being filed.

     

    G.

    Each person filing this Form, other than a trustee filing in accordance with General Instruction I. (a) of this Form, undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to: the Forms, Schedules and offering statements described in General Instructions I. (a), I. (b), I. (c), I. (d) and I. (f) of this Form, as applicable; the securities to which such Forms, Schedules and offering statements relate; and the transactions in such securities.

    The Filer certifies that it has duly caused this power of attorney, consent, stipulation and agreement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Taipei City Country of Republic of China this 15th day of September, 2021 ..

     

     

     


    Filer:     WOODS INVESTMENT CO., LTD.
        By:  

    /s/ George Yeh

        Name:   George Yeh
        Title:   Director

    This statement has been signed by the following persons in the capacities and on the dates indicated.

     

    TLC Biopharmaceuticals, Inc. as Agent for Service of
    Process for Woods Investment Co., Ltd.
    By:  

    /s/ George Yeh

    Name:   George Yeh
    Title:   President
    Date: September 15, 2021
    Get the next $TLC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLC

    DatePrice TargetRatingAnalyst
    7/13/2021$11.00 → $7.50Buy → Neutral
    H.C. Wainwright
    7/7/2021Buy → Hold
    Laidlaw
    More analyst ratings

    $TLC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Taiwan Liposome downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Taiwan Liposome from Buy to Neutral and set a new price target of $7.50 from $11.00 previously

    7/13/21 7:44:05 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    Taiwan Liposome downgraded by Laidlaw

    Laidlaw downgraded Taiwan Liposome from Buy to Hold

    7/7/21 7:42:46 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    $TLC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TLC Announces TLC599 Agreement with Endo

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with Endo International plc (NASDAQ:ENDP) for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain. Under the terms of the agreement, signed with Endo's subsidiary Endo Ventures Limited (EVL), TLC will primarily be responsible for the development of the product and EVL will primarily be responsible fo

    6/13/22 6:30:00 AM ET
    $ENDP
    $TLC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy. TLC599 is a proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) intended for the treatment of osteoarthritis pain. The results demonstrated statistically significantly reduced pain scores and oral pain medication use for up to 6 months wit

    3/7/22 4:57:07 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares

    This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exemption from the registration requirements of the Securities Act provided by Rule 802 thereof. No public offering of such securities will be made in the United States. Such transaction has not been and

    9/8/21 4:40:55 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    $TLC
    SEC Filings

    View All

    SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    CB/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    10/14/21 8:58:32 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    CB/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    10/8/21 4:00:37 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Taiwan Liposome Company, Ltd.

    6-K - Taiwan Liposome Company, Ltd. (0001722890) (Filer)

    10/8/21 11:56:31 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    $TLC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    1/7/22 8:15:09 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    11/12/21 6:05:15 AM ET
    $TLC
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)

    SC 13D/A - Taiwan Liposome Company, Ltd. (0001722890) (Subject)

    10/20/21 4:08:25 PM ET
    $TLC
    Major Pharmaceuticals
    Health Care